Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis? - 06/10/15
Doi : 10.1016/j.jaci.2015.06.011
Avraham Beigelman, MD, MSCI a 
, Leonard B. Bacharier, MD a, Jack Baty, BA b, Richard Buller, PhD a, Sheila Mason, BHS a, Kenneth B. Schechtman, PhD b, Geneline Sajol, BSc c, Megan Isaacson-Schmid, BSc a, Mario Castro, MD, MPH c, Gregory A. Storch, MD a
, Leonard B. Bacharier, MD a, Jack Baty, BA b, Richard Buller, PhD a, Sheila Mason, BHS a, Kenneth B. Schechtman, PhD b, Geneline Sajol, BSc c, Megan Isaacson-Schmid, BSc a, Mario Castro, MD, MPH c, Gregory A. Storch, MD a a Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
b Division of Biostatistics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
c Department of Internal Medicine, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
| This study was supported by the Washington University Institute of Clinical and Translational Sciences (grant no. UL1 TR000448 from the National Center for Advancing Translational Sciences, subaward KL2 TR000450) and the Children's Discovery Institute of Washington University and St Louis Children's Hospital. This study was supported in part (REDCap database) by the National Institutes of Health's Clinical and Translational Science Award (CTSA) (grant no. UL1 TR000448) and the Siteman Comprehensive Cancer Center and the National Cancer Institute (NCI) Cancer Center (support grant no. P30 CA091842). |
|
| Disclosure of potential conflict of interest: L. B. Bacharier has received research support from the National Institutes of Health (NIH) and from National Heart, Lung, and Blood Institute/NIH AsthmaNet and has received consultancy fees from Aerocrine, AstraZeneca, Genentech/Novartis, GlaxoSmithKline, Merck, Schering, and Teva. M. Castro has received grants from the NIH during the conduct of the study; personal fees from Asthmatx/Boston Scientific, IPS/Holaria, Genentech, Merck, GSK, Genentech, Boehringer-Ingelheim, and Elsevier; grants from Boston Scientific, Amgen, Ception/Cephalon/Teva, Genetech, Medimmune, Merck, Novartis, GSK, Sanofi-Aventis, Vectura, NextBio, and KalaBios; and stock options from Sparo, Inc, all outside the submitted work. The rest of the authors have received research support from the NIH. |
© 2015
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 136 - N° 4
P. 1129-1131 - octobre 2015 Retour au numéro
Article précédent
- Comparison of risk factors for viral and nonviral asthma exacerbations
- Amaziah T. Coleman, Daniel J. Jackson, Ronald E. Gangnon, Michael D. Evans, Robert F. Lemanske, James E. Gern
- Wheat oral immunotherapy for wheat-induced anaphylaxis
- Sakura Sato, Tomohiro Utsunomiya, Takanori Imai, Noriyuki Yanagida, Tomoyuki Asaumi, Kiyotake Ogura, Yumi Koike, Noriko Hayashi, Yu Okada, Akinori Shukuya, Motohiro Ebisawa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?